Allergan Aesthetics Completes Acquisition of Soliton

Allergan Aesthetics' portfolio of non-invasive body contouring treatments now includes the RESONIC device to treat cellulite.

It’s official: Allergan Aesthetics, an AbbVie company, completed its acquisition of Soliton, Inc. 

The addition of Soliton and its technology complements Allergan Aesthetics' portfolio of non-invasive body contouring treatments to now include the RESONIC device.

This device initially received U.S. Food and Drug Administration (FDA) 510(k) clearance for the short-term improvement in the appearance of cellulite, and that clearance has now been expanded to long-term improvement up to one year. In recent clinical data submitted to the FDA, RESONIC demonstrated significant improvement in the appearance of cellulite and 97.6 percent of participants (n=67) found there was good improvement in the appearance of cellulite at 52-weeks post-treatment.  

"We welcome the Soliton team to Allergan Aesthetics and the opportunity to offer health care providers and their patients a new, non-invasive option to reduce the appearance of cellulite," says Carrie Strom, President, Global Allergan Aesthetics and Senior Vice President, AbbVie, in a news release. "In a recent survey of aesthetics consumers, cellulite was cited as a top 5 aesthetic concern, and this technology offers a new approach to treatment."

RESONIC has also received FDA 510(k) clearance for use in conjunction with laser for black ink tattoo removal in Fitzpatrick Skin Type I-III patients.